CD86 and cancer: In sentinel lymph nodes, mature DCs (identified as CD86+MHC II+) increased robustly in the HA-man@Fe3O4 plus HA-man@Fe3O4@pep group, while free peptides failed to arouse mature DCs, suggesting the necessity of adjuvant and carrier in cancer vaccination (Figure 8).